Rheumatology A
CDAI — Clinical Disease Activity Index (RA)
Clinical Disease Activity Index for RA — does not require lab tests, making it useful at point of care.
Score interpretation
Remission 0–2.8
CDAI ≤2.8: Remission
→ Maintain therapy; consider tapering if sustained
Low Disease Activity 2.9–10
CDAI 2.9–10: Low disease activity
→ Continue optimising treatment; aim for remission
Moderate Disease Activity 10.1–22
CDAI 10.1–22: Moderate disease activity
→ Review DMARDs; consider escalation or combination therapy
High Disease Activity 22.1–76
CDAI >22: High disease activity
→ Urgent DMARD escalation; biologic assessment; rheumatology review
Interpretation bands for the CDAI. Apply clinical judgement and local guidance.
References
- Aletaha D, Smolen JS. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI). Clin Exp Rheumatol. 2005;23(5 Suppl 39):S100-108.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Hydroxychloroquine · Aminoquinoline — Malaria Prophylaxis / SLE / Rheumatoid Arthritis
- Pindolol · Non-selective β-blocker (with intrinsic sympathomimetic activity)
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Sulfasalazine · Aminosalicylate / Disease-Modifying Antirheumatic Drug (DMARD)
Pathways
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.